Oncolytics Biotech has found that a naturally occuring reovirus has enormous potential for treating cancer. This reovirus has been found to attack cancer cells while ignoring healthy cells. It is a naturally occuring virus and is non-pathogenic. It has been found to attack about 2/3 of human cancers including breast, prostate and brain cancer. There are a number of independent studies documenting reovirus therapy .
According to their site this is how the virus operates:
Additionally, the research has shown enough promise to warrant a grant from the U.S. National Cancer Institute.
http://biz.yahoo.com/prnews/031029/to193_1.html
According to their site this is how the virus operates:
Scientific studies have demonstrated that approximately two-thirds of all human cancer cells have an activated Ras pathway, one of the most common set of mutations leading to cancer. An activated Ras pathway leads to a constant barrage of growth signals to the cell, causing uncontrolled growth. In cells with an activated Ras pathway, the anti-viral response appears to be turned off. When reovirus infects one of these cancer cells, it is able to replicate and eventually kill the cancer cell. Up to 5,000 progeny virus organisms can then infect and kill surrounding cancer cells. Theoretically, the cycle of infection, replication and cell death will continue until there are no longer any cancer cells accessible.
Additionally, the research has shown enough promise to warrant a grant from the U.S. National Cancer Institute.
CALGARY, Oct. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that support for multiple clinical trials to evaluate the efficacy of REOLYSIN® in a range of cancers has been approved by the Drug Development Group of the Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute ("NCI").
http://biz.yahoo.com/prnews/031029/to193_1.html